rs1044471 — ADIPOR2 ADIPOR2 3'UTR variant

ADIPOR2 rs1044471 — The Liver's Adiponectin Switch

Adiponectin is one of the few hormones released by fat tissue that actually protects against metabolic disease: it rises with fat loss, improves insulin sensitivity, suppresses hepatic glucose production, and drives fatty acid oxidation¹¹ fatty acid oxidation
the breakdown of stored fat for fuel, primarily in liver and skeletal muscle through AMPK and PPARα pathways. The receptor through which adiponectin acts in the liver is ADIPOR2 (Adiponectin Receptor 2, gene symbol ADIPOR2, chromosome 12p13.33). Unlike its counterpart ADIPOR1 — the predominant skeletal-muscle receptor — ADIPOR2 is predominantly expressed in hepatic tissue, where it couples adiponectin signaling to PPARα²² PPARα
Peroxisome proliferator-activated receptor alpha, a nuclear receptor that upregulates fatty acid β-oxidation enzymes and suppresses hepatic gluconeogenesis and pro-inflammatory gene programs. Disrupting ADIPOR2 expression in cell models impairs hepatic fat oxidation and worsens insulin resistance, establishing a clear mechanistic link between receptor activity and metabolic homeostasis.

rs1044471 is located in the 3' untranslated region (3'UTR) of ADIPOR2 at GRCh38 position chr12:1,787,789 (plus strand). The 3'UTR is a regulatory region that influences mRNA stability, translation efficiency, and microRNA binding — variants here can alter how much functional ADIPOR2 protein the liver produces without changing the protein's amino acid sequence. The reference C allele (frequency ~61% globally) is the more common variant and is associated with adverse metabolic signals in diabetic subjects. The T allele (~39% globally) appears to confer metabolic and oncological protection in multiple independent studies.

The Mechanism

The 3'UTR position of rs1044471 means it likely influences post-transcriptional regulation³³ post-transcriptional regulation
control of gene expression that occurs after the DNA has been transcribed into mRNA; includes mRNA stability, splicing, and the ability of microRNAs to silence translation of ADIPOR2 rather than changing the receptor protein itself. The C allele may alter a microRNA-binding site or an RNA-binding protein interaction that reduces ADIPOR2 mRNA stability or translation efficiency in the liver, effectively reducing the density of functional receptors available to transduce adiponectin signals. A reduced receptor density would dampen AMPK and PPARα activation — leaving the liver less able to oxidize incoming fatty acids, more prone to accumulating triglycerides, and less responsive to adiponectin's anti-inflammatory and insulin-sensitizing signals. This mechanistic picture is consistent with the observed associations but has not been confirmed by functional studies characterizing the allele-specific 3'UTR effect at this site.

The Evidence

The clearest metabolic signal for rs1044471 comes from a López-Bermejo et al. 2008⁴⁴ López-Bermejo et al. 2008
Cross-sectional study of 700 white subjects stratified by glucose tolerance status; examined ADIPOR2 SNPs in relation to circulating adiponectin and liver function tests. The key finding was context-dependent: in non-diabetic subjects, the C-allele-associated genotypes were linked to higher circulating adiponectin (P<0.05), while in type 2 diabetic subjects the same alleles were associated with elevated serum ALT and AST (P<0.05 to P<0.0001) — liver enzymes that rise when hepatocytes are damaged or under lipotoxic stress. This paradox suggests the C allele may represent a compensatory upregulation of adiponectin secretion in non-diabetic individuals, which then fails in the insulin-resistant state, unmasking hepatic lipotoxicity driven by impaired ADIPOR2-mediated fatty acid oxidation.

A Korean study of 757 type 2 diabetic patients and 644 controls Kim et al. 2009⁵⁵ Kim et al. 2009
Case-control study genotyping ADIPOR1 and ADIPOR2 polymorphisms in a Korean population; no association with T2D risk was found for any SNP found that the T allele (g.33447T, equivalent to our T allele) was associated with smaller waist circumference — a favorable anthropometric phenotype reflecting less visceral adiposity. No association with T2D susceptibility was found in this population.

Two cancer association studies converge on the same protective direction for the T allele. Ye et al. 2013⁶⁶ Ye et al. 2013
Chinese Han case-control study examining ADIPOQ and ADIPOR2 variants in gastric cancer found that the minor T allele of rs1044471 was associated with a 30% reduction in cardia (upper stomach) cancer risk (OR 0.703, 95% CI 0.519–0.951, P=0.022). Zhou et al. 2017⁷⁷ Zhou et al. 2017
Case-control study of 281 CRC patients vs. 325 controls in Chinese Han subjects; AdipoR2 protein expression also measured in tumor tissue found the CC genotype to be an independent risk factor for colorectal cancer, associated with worse tumor differentiation and higher Dukes staging. Taken together, these findings suggest the C allele impairs adiponectin receptor signaling in a way that reduces the anti-proliferative and anti-inflammatory protection adiponectin normally exerts in the gastrointestinal tract and liver.

Evidence for T2DM susceptibility is mixed: the Korean cohort showed no association, and the UK Collins et al. 2007 Diabetologia study of 2,127 subjects and 24 ADIPOR2 SNPs found no T2D association for any variant tested.

Practical Actions

For individuals carrying the CC genotype, the evidence supports monitoring liver health markers (ALT, AST, GGT) — particularly if other metabolic risk factors are present — and strategies that support hepatic adiponectin signaling. Adiponectin receptor activity can be enhanced by dietary patterns that reduce hepatic lipid load: limiting dietary fructose (which drives hepatic de novo lipogenesis through ChREBP, the same pathway ADIPOR2 suppresses) and ensuring adequate long-chain omega-3 intake, which upregulates PPARα and mimics some downstream effects of adiponectin receptor activation.

For CT and TT carriers, the T allele appears to shift the metabolic balance toward improved adiponectin receptor sensitivity, smaller waist circumference, and reduced gastrointestinal cancer risk — effects likely mediated through enhanced ADIPOR2-dependent PPARα activation in the liver.

Interactions

rs1044471 co-exists in the ADIPOR2 gene alongside rs11061946 and rs11061937 (intronic variants), rs1342387, and rs10773989. In the Zhang et al. 2018 myocardial infarction study, rs1044471 was identified alongside rs1342387 and rs10773989 as a significant contributor in logistic regression — suggesting that ADIPOR2 haplotype effects across multiple variants may compound the metabolic and cardiovascular risk beyond what any single SNP explains.

The adiponectin pathway involves ADIPOQ (the adiponectin gene itself) and ADIPOR1 (the complementary muscle-expressed receptor). Variants in ADIPOQ that reduce circulating adiponectin concentrations would diminish the ligand available to activate ADIPOR2 — meaning that ADIPOQ and ADIPOR2 variants may combine to produce a larger deficit in hepatic adiponectin signaling than either alone.